FY2026 EPS Estimates for Ekso Bionics Reduced by Analyst

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Ekso Bionics in a research note issued to investors on Tuesday, October 29th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.02 per share for the year, down from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Ekso Bionics’ FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.43 EPS.

Other analysts also recently issued reports about the stock. Lake Street Capital lowered their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com started coverage on Ekso Bionics in a research note on Saturday, October 26th. They issued a “hold” rating for the company.

Ekso Bionics Trading Down 8.2 %

Shares of EKSO opened at $0.86 on Wednesday. Ekso Bionics has a fifty-two week low of $0.83 and a fifty-two week high of $3.13. The firm has a market cap of $15.56 million, a price-to-earnings ratio of -0.92 and a beta of 1.45. The firm has a 50 day moving average price of $1.11 and a 200-day moving average price of $1.15. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42.

Ekso Bionics (NASDAQ:EKSO) last issued its earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same period in the prior year, the company earned ($0.24) EPS.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.